#USA #Avid Bioservices #Tustin, California #Biologics CDMO #Dave Stewart

Avid Bioservices Welcomes Dave Stewart as Chief Technology and Transformation Officer

Avid Bioservices, Inc., a prominent organization in the biologics contract development and manufacturing sector, has recently announced the appointment of Dave Stewart as its new Chief Technology and Transformation Officer (CTTO). This newly established role aims to support Avid’s ambitious agenda for growth and innovation in the rapidly evolving field of biologics manufacturing.

A Significant Step in Avid's Growth Strategy

The induction of Stewart as CTTO marks an essential milestone in the firm's trajectory as outlined by CEO Kenneth Bilenberg. Recognizing the need for strategic investments in talent, technology, and systems, Bilenberg sees Stewart's expertise as vital for steering the company through its next phase, ensuring Avid remains the most reliable and proactive partner for its clients.

“Avid has built tremendous momentum over the past several years,” Bilenberg stated. “And as we look ahead, we are making deliberate investments in people, processes and the systems that will power our future.” His confidence in Stewart underscores the significant role this position will play in fostering reliability and predictability at every phase of client interaction.

Steward’s Vision and Role

In his newfound position, Stewart will lead initiatives focused on the integration of advanced technologies and the transformation of operational processes across Avid's manufacturing network. His responsibilities will include spearheading efforts in digital modernization and automation, as well as adopting new tools that will enhance service capabilities.

As Avid plans to expand its operational capacity, Stewart is keen on ensuring that the company's systems are aligned for maximum efficiency and adaptability. His commitment to improving processes stresses the company’s overarching goal: to be known for reliability and quality in service to its clients and their patients.

“I've long admired Avid's reputation for quality and its unwavering focus on patients,” Stewart remarked. His belief in Avid’s mission and his appreciation for the employee commitment at Avid reflect a collective ambition to prioritize excellence.

Avid’s Commitment to Innovation

The creation of the CTTO role reaffirms Avid’s dedication to ongoing improvement and fostering strong client partnerships. It symbolizes the company’s readiness to adapt, innovate, and expand its capabilities. This strategic move is crucial in a field where agility and expertise are vital for maintaining competitive advantage.

Avid Bioservices has positioned itself as a leader in mammalian cell-culture manufacturing, boasting an exemplary FDA record and earning the trust of biopharmaceutical innovators across the globe. Drawing from rich experience with both emerging biotechs and major multinational pharmaceutical companies, Avid stands out by offering comprehensive end-to-end solutions from initial development through to commercial supply.

Celebrating Avid’s Achievements

The company has successfully produced over 600 batches and delivered more than 275 commercial batches worldwide, amplifying its impact in the industry. With six approved commercial products and ten successful pre-approval inspections across significant regulatory agencies, Avid is committed to navigating complex regulatory landscapes efficiently.

In summary, the appointment of Dave Stewart as the Chief Technology and Transformation Officer signifies a new chapter in Avid Bioservices’ ongoing story of growth and excellence. With a strategic focus on technological integration and process evolution, Avid is set to emerge stronger, further enhancing its capabilities to deliver exceptional service to its clients and the patients they serve.